Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2025-08-22 00:00:00 ET · period of report 2025-08-21 · accession 0001415889-25-022760 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-08-22 | 2025-08-21 | SPRY | Scott Kathleen D. | CFO | M - OptEx | $1.50 | +12.5K | 22.5K | +124% | +$18.8K |
| D | 2025-08-22 | 2025-08-21 | SPRY | Scott Kathleen D. | CFO | S - Sale+OE | $15.00 | -12.5K | 10.0K | -55% | -$187.5K |
| D | 2025-08-22 | 2025-08-21 | SPRY | Scott Kathleen D. | CFO | M - OptEx | $0.00 | -12.5K | 739.8K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-21 | M | A | 12,500 | $1.50 | 22,542 | D | — | — | (F1) Includes 2,618 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2025. |
| 2 | Common | Common Stock | 2025-08-21 | S | D | 12,500 | $15.00 | 10,042 | D | — | — | (F2) The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on May 22, 2025. |
| 3 | Derivative | Stock Option (Right to Buy) | 2025-08-21 | M | D | 12,500 | $0.00 | 739,830 | D | $1.50 · — to 2032-02-29 | 12,500 Common Stock | (F3) Immediately exercisable. |